A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis.
about
Developments with experimental and investigational drugs for axial spondyloarthritis.New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agents.Therapies of Early, Advanced, and Late Onset Forms of Axial Spondyloarthritis, and the Need for Treat to Target Strategies.The use of the tyrosine kinase inhibitor Nilotinib in Spondyloarthritis: does targeting inflammatory pathways with a treatment lead to vascular toxicity?Targeted synthetic disease-modifying antirheumatic drugs in spondyloarthritis.
P2860
A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A proof-of-concept study with ...... ilotinib in spondyloarthritis.
@en
A proof-of-concept study with ...... ilotinib in spondyloarthritis.
@nl
type
label
A proof-of-concept study with ...... ilotinib in spondyloarthritis.
@en
A proof-of-concept study with ...... ilotinib in spondyloarthritis.
@nl
prefLabel
A proof-of-concept study with ...... ilotinib in spondyloarthritis.
@en
A proof-of-concept study with ...... ilotinib in spondyloarthritis.
@nl
P2093
P2860
P1476
A proof-of-concept study with ...... ilotinib in spondyloarthritis.
@en
P2093
Dominique Baeten
Iris C Blijdorp
Jacqueline E Paramarta
Maureen C Turina
Nataliya Yeremenko
Tanja F Heijda
Troy Noordenbos
P2860
P2888
P356
10.1186/S12967-016-1050-2
P577
2016-10-27T00:00:00Z
P6179
1048043210